Here’s what you should know:
1. Ambu agreed to make contingent payments up to €110 million ($129 million) as part of the deal. The contingencies were not disclosed.
2. Invendo Medical develops sterile, single-use, high-definition endoscopy products for gastroenterologists. Invendo developed the world’s first single-use GI platform.
3. In 2018, Invendo expects its HD colonoscope to earn both FDA approval and a CE mark.
4. Invendo has been active in the single-use pulmonary endoscopy field to the tune of 5 million annual procedures.
Ambu CEO Lars Marcher said in a release, “This acquisition is a massive upgrade of our business potential. We introduced single-use endoscopy for airway procedures with the Ambu aScope, and now, we will get ready to introduce single-use for the gastrointestinal procedures. This is an important acquisition that puts Ambu in an ideal position to further disrupt the reusable market within endoscopy.”
More articles on gastroenterology:
GI leader to know: Dr. Umaprasanna Karnam of Gut Whisperer Center for Digestive Health
Stock market week-in-review for 5 large GI companies — Oct. 16-20
To prevent injury, gastroenterologists should complete more ergonomics training, take breaks
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.